AMYLYX PHARMACEUTICALS INC (AMLX) Stock News

Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia

Is Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) the Best Biotech Penny Stock to Buy According to Hedge Funds?

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) stands against other biotech penny stocks. Peter Marks’s departure from the FDA has left innovators concerned regarding the current state of […]

Mentions: PLTR AAPL USB

Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis

4 Analysts Assess Amylyx Pharma: What You Need To Know

Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Mentions: LAZ OMI MOMO LDI ...

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025

Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference

Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results

Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Why Amylyx Pharmaceuticals Stock Was So Healthy This Week

The company seems to have a winner on its hands with a drug that targets a rare genetic disorder.

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc....

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and Neurodegeneration

Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results

Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc....

Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation

Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide